This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

Evolus, Inc.
11/4/2026
Good afternoon, everyone, and thank you for standing by. Welcome to Evelus' third quarter earnings conference call. As a reminder, today's conference is being recorded and webcast live. All participants are in a listen-only mode. After the speaker's remarks, there will be a question-and-answer session. If you'd like to enter the queue at any time, please press star 1 on your telephone keypad. I would now like to turn the conference over to your host, Nareg Sagherian.
Thank you, Operator, and welcome to everyone joining us on today's call to review Avalos' third quarter financial results. Our third quarter press release is now available on the investor relations section of our website at avalos.com. Joining me on today's call are David Moatazedi, President and Chief Executive Officer, Rui Avelar, Chief Medical Officer and Head of R&D, and Tatjana Mitchell, Chief Financial Officer. Today's call will include forward-looking statements. Actual results may differ materially due to risks and uncertainties outlined in our earnings press release and SEC filings. These forward-looking statements are based on current assumptions, and we undertake no obligation to update them. Additionally, we will discuss certain non-GAAP financial measures. These measures should be considered in addition to and not as a substitute for our GAAP results. A reconciliation of GAAP to non-GAAP measures is included in today's earnings release. As a reminder, our earnings release and SEC filings are available on the SEC's website and on our investor relations website. Following the conclusion of today's call, a replay will be available on our website at investors.avelus.com. With that, I'll turn the call over to our CEO, David Moatazedi.
Thank you, Nareg, and good afternoon, everyone. I'm pleased to report our fourth consecutive quarter of positive adjusted EBITDA and continued above-market growth while continuing to expand our portfolio with differentiated assets. These results reflect our deliberate strategy to build on the strength of our established brand while creating additional opportunities for long-term growth. Avelus is now a more diversified global performance beauty company with a growing international commercial portfolio, an expanding pipeline, and improving financial performance. At the beginning of the year, we outlined three priorities to guide our progress, commercial execution, Financial Discipline, and Pipeline Expansion. Let me update you on each priority. On Commercial Execution, Global Toxin Revenue grew approximately 11% both in the third quarter and year-to-date, while our newly launched HA Business grew nearly 40% in the quarter and more than 50% year-to-date. On Financial Discipline, We delivered our fourth consecutive quarter of positive adjusted EBITDA while continuing to invest in our commercial priorities and portfolio development. Importantly, through the first nine months, revenue grew 14% while we maintained nearly flat non-GAAP operating expenses, demonstrating the outstanding leverage of our portfolio of products. On pipeline expansion, We've added skin quality as a third pillar within our U.S. facial injectable pipeline through our partnership with IFSA for Profilo. We also recently announced an early-stage option agreement in procedure-based injectable hair growth, which adds a longer-term opportunity in a complementary aesthetic category. Turning to the quarter, we are operating in a healthy global aesthetics market. with consumers continuing to prioritize beauty and their appearance despite softer consumer confidence. We believe the category is strengthening in the U.S., supported in part by broader adoption of GLP-1 therapies, which is bringing new patients into aesthetic practices and creating additional treatment needs following weight loss. These strong tailwinds reinforce our confidence in the opportunity ahead. We delivered $78 million in revenue in the third quarter, up 13% year-on-year. Through the first nine months, adjusted EBITDA reached positive $6.4 million compared with a loss of $16.5 million a year ago, an improvement of approximately $23 million. These results demonstrate our progress in translating commercial growth into improved financial performance while continuing to make investments in the business. Javeau remains the foundation of our commercial platform. Its continued growth reflects our focus on customer experience, clinical education, and consumer loyalty, which supports, share gains, and strengthens our relationships with aesthetic practices. As we expand the portfolio, our established relationships and infrastructure have provided an opportunity to introduce complementary bands and become a more meaningful partner for our clinics. We are seeing that opportunity develop with our Evelisse portfolio. More than 4,500 customers have now purchased Evelisse, providing a foundation for continued adoption and increased utilization within practices. Our focus remains on building confidence with the portfolio through education, service, and experience with the product. As we did with Jouveau, we are converting initial adoption into sustained use. increasing the overall value of our partnership within aesthetic practices. Our growth continues to be supported by an expanding customer base and sustained consumer engagement. During the quarter, we added over 500 purchasing accounts, bringing our cumulative customer base to more than 19,000. Avalyst Rewards membership grew 23% year-over-year to more than 1.6 million consumers. with approximately 70% of existing patients returning for repeat treatment. Together, these trends demonstrate our ability to attract new patients to practices and build the loyalty that supports sustained growth as we continue to expand the portfolio. Internationally, we are extending the same portfolio approach. Following the successful launch of Esteem in Europe, we expanded our relationship with Cimetase in August to include Canada, Australia, and New Zealand. We now hold exclusive rights to the Avelis portfolio in every market where we currently offer Jouveau and Nuciva. Strategically, this alignment gives us the opportunity to build a consistent multi-product offering across our global business with a broader set of brands supported by our existing commercial infrastructure. Our financial performance this year demonstrates the operating leverage that makes this portfolio strategy compelling. We are growing revenue and improving profitability through a platform designed to support multiple injectable brands. Additional products can address more treatment needs within the same practices, allowing us to build on existing customer relationships, digital capabilities, and commercial infrastructure. This platform provides a commercial foundation for the next stage of our US portfolio. As we look ahead, we plan to introduce three additional products over the next four years. This expansion builds on Juveau and the first two formulations of Evelisse. Within Evelisse, we expect Sculpt to be our next launch, followed by Lips. Beyond these launches, our partnership with IPSA supports U.S. development and commercialization of Profilo, the market-leading skin-quality injectable in Europe. We are also building opportunities beyond that launch horizon. Our early-stage option agreement in procedure-based injectable hair growth adds a longer-term opportunity that is complementary to the aesthetic practices we serve. This gives us a portfolio spanning established commercial products, products advancing toward anticipated launches, and earlier-stage opportunities that can broaden our growth over time. With that, I'd like to turn the call over to Rui to talk you through the portfolio in more detail, beginning with our commercial products. He will then update you on the products advancing through development and regulatory review, followed by our longer-term opportunities.
You're reading a preview of the EOLS Q3 2026 earnings call.
Free account.
Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.
Use this data in your own app
Pull this call's transcript, audio and slides with the Earnings call transcripts API.
See pricing